Cumulus Neuroscience
Classification
Private
Financials
Revenue & Profit
Valuation
Ratios
People
Deals
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
Funding
About
About
Cumulus Neuroscience is a privately-held company that provides "real-world" clinical trial data and AI-powered insights via an integrated biomarker platform co-developed with some of the world's leading pharmaceutical companies. The company's integrated solution is a platform capable of capturing frequent, longitudinal measurements of brain activity synchronously with a comprehensive range of functional and symptomatic domains outside of the clinic, and providing insights, powered by AI techniques, to support clinical trial decision making and execution. Cumulus Neuroscience was founded in 2015 by Brian Murphy Ph.D and Ronan Cunningham. Cumulus Neuroscience headquarters are located in Belfast, United Kingdom. Cumulus Neuroscience was formerly known as BrainWaveBank.
Keywords
Keywords
Classified
Private